# Opus Genetics, Inc.: Form 10-K for the period ended Dec 31, 2019

- Company: [Opus Genetics, Inc.](/companies/ird.md) (CIK 1228627)
- Form: 10-K
- Filed: 2020-02-21
- Accepted by EDGAR: Feb 21, 2020, 16:39 ET
- Period: 2019-12-31
- Accession: 0001140361-20-003785
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1228627/000114036120003785/form10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1228627/000114036120003785/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2019-01-01 to 2019-12-31 | $3.0m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 12 months, 2019-01-01 to 2019-12-31 | $5.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2019-01-01 to 2019-12-31 | −$11.2m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months, 2019-01-01 to 2019-12-31 | −$8.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2019-01-01 to 2019-12-31 | −$2.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2019-01-01 to 2019-12-31 | −$10.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2019-12-31 | $12.7m | us-gaap:AssetsCurrent |
| Total assets | at 2019-12-31 | $13.0m | us-gaap:Assets |
| Current liabilities | at 2019-12-31 | $2.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-12-31 | $3.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-12-31 | $10.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1228627/000114036120003785/form10k.htm

Filed Feb 21, 2020.
Source: SEC EDGAR, the filing index for accession 0001140361-20-003785. Last ingested by Listed: Nov 12, 2026, 19:22 ET. No prices; not investment advice.
